Nomura Securities Downgrades Valeant Pharmaceuticals (VRX) to Neutral
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/23/2026
- Wall Street ends lower on semiconductor selloff as AI spending concerns mount
- Chip stocks plunge, but bargain-hunters stem losses in other tech names
- FedEx falls 4% as FY2027 profit forecast misses expectations despite Q4 beat
- Oil prices finish 1% lower as investors focus on Hormuz flows after peace talks
- South Korea leveraged ETF crisis sparks global chip selloff
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
- Spain's ex-transport minister sentenced to 24 years for corruption
- China, US, UAE police arrest 276 telecom fraud suspects in Dubai
- Needham Starts NeoVolta (NEOV) at Buy
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
Valeant Pharma (VRX) Price Target Lowered to $45 at TD Securities
March 16, 2016 11:16 AM EDTTD Securities earlier maintained a Hold rating on Valeant Pharmaceuticals (NYSE: VRX) and lowered its price target to $45.00 (from $110.00). The change follows updated guidance announced yesterday.
Analyst Lennox Gibbs said, "This latest revision layers on to an already protracted decline in... More
Valeant (VRX) PT Cut to $53 at Jefferies
March 16, 2016 11:05 AM EDTJefferies analyst David Steinberg lowered his price target on Valeant Pharmaceuticals (NYSE: VRX) to $53.00 (from $106.00) but maintained his Buy rating after shares were pummeled yesterday on weak guidance.
Steinberg commented, "VRXs highly anticipated FY16 guidance was much lighter than expected as key... More
Valeant Pharma (VRX) Adds to Gains on Rumor
March 16, 2016 10:12 AM EDTValeant Pharma (NYSE: VRX) is adding to early gains on a vague rumor Carl Icahn could become involved in the name. Shares are up 3.1%.
For what its worth, Icahn rumors are almost 100% wrong and the last thing the stock needs is another hedge fund manger involved.
... MoreValeant Pharma (VRX) Sees Early Upside after Massive Beating
March 16, 2016 9:48 AM EDTAfter staring lower, Valeant Pharma (NYSE: VRX) is up 2.7% today after getting annihilated to the tune of 51% on Tuesday.
... MoreValeant (VRX) PT Cut to $40 at Canaccord Genuity
March 16, 2016 9:40 AM EDTCanaccord Genuity analyst Neil Maruok reiterated a Hold rating and lowered his price target on Valeant Pharmaceuticals (NYSE: VRX) to $40.00 (from $75.00).
Maruok commented, "guidance was even lower than our base-case scenario and we believe has begun to erode investor confidence in Valeants underlying business. We believe that the implementation of the partnership with Walgreens,... More
Valeant (VRX) Default 'Unlikely', Says Rodman & Renshaw
March 16, 2016 7:43 AM EDTRodman & Renshaw reiterated a Buy rating on Valeant Pharmaceuticals (NYSE: VRX) with a modified price target of $118.00 (from $150.00). The change follows soft guidance issued yesterday. Analyst Raghurum Selvaraju noted that the stock's plunge was motivated by fear of default, which he sees as unlikely.
Selvaraju explained, "From our perspective, the main hurdle at this juncture for Valeant is the lack of credibility... More
